InMode (INMD) closed at $21.61 in the latest trading session, showing a positive move of +1.93% from the previous day. This performance outpaced the S&P 500’s daily gain of 0.11%, while the Dow saw a gain of 0.12% and the Nasdaq experienced a decrease of 0.12%.
Over the past month, shares of InMode have declined by 2.21%, falling behind the Medical sector’s gain of 0.46% and the S&P 500’s gain of 3.55% during the same period.
Investors are eagerly anticipating InMode’s upcoming earnings disclosure, with predictions of an EPS of $0.53, a 1.92% growth from the same quarter last year. Revenue is estimated to be $104.3 million, a 1.67% decrease from the previous year’s quarter.
Looking at the full fiscal year, Zacks Consensus Estimates forecast earnings of $2.56 per share and revenue of $500.8 million, indicating changes of -0.39% and +1.78%, respectively, from the prior year.
Analyst forecasts for InMode are crucial, as recent revisions can indicate short-term business trends. Positive estimate revisions are seen as a sign of optimism about the company’s future performance.
In terms of valuation, InMode currently has a Forward P/E ratio of 8.28, representing a discount compared to the industry average of 22.56.
The Medical – Products industry, to which InMode belongs, has a Zacks Industry Rank of 89, placing it in the top 36% of all industries. Industries with higher Zacks Industry Ranks tend to outperform those with lower ranks.
Investors are advised to monitor stock-impacting metrics and rely on Zacks.com for updates in the upcoming trading sessions.
